Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma	B-cell neoplasm, Chemically-Induced Disorders, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, nervous system disorder, poisoning, toxic encephalopathy	Active, not recruiting	Phase 1	2026-07-31		NCT03696784

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
M.D. Anderson Cancer Center	1145
National Cancer Institute (NCI)	3015
The V Foundation	8
UNC Chapel Hill University Cancer Research Fund	1
UNC Lineberger Comprehensive Cancer Center	125

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill	Chapel Hill	United States	7